<DOC>
	<DOCNO>NCT00647270</DOCNO>
	<brief_summary>To demonstrate efficacy 80 mg adalimumab monthly dosing compare placebo demonstrate non-inferiority monthly dose 80 mg adalimumab compare dose 40 mg adalimumab every week .</brief_summary>
	<brief_title>Study Comparing 80 mg Adalimumab With Placebo , Demonstrating Non-inferiority Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing</brief_title>
	<detailed_description>The objective study demonstrate efficacy 80 mg adalimumab monthly dosing compare placebo measure ACR20 response criterion follow 12 week therapy . The study also design demonstrate non-inferiority monthly dose 80 mg adalimumab compare dose 40 mg adalimumab eow measure ACR20 response criterion Week 12 .</detailed_description>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subject &gt; 18 year age Subject diagnosis RA define 1987revised ACRclassification criterion disease duration minimum three month Subject must meet follow two criterion : ) At least 6 swollen joint 66 assess , b ) At least 6 tender joint 68 assessed If subject MTX , dose must stable least 4 week prior Screening blood draw follow standard recommendation MTX treatment Subject judge generally good health determine principal investigator Subject previous exposure systemic antiTNF therapy ( eg , infliximab , etanercept , certolizumab pegol golimumab ) include adalimumab Subject history acute inflammatory joint disease different origin RA Subject treat investigational biologic agent Subject consider investigator , reason , unsuitable candidate study Female subject pregnant breastfeeding consider become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>